Holen Sie sich die Stockscreener-App
18.21
1.41%
-0.26
Handel nachbörslich:
18.12
-0.09
-0.49%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$18.47
Offen:
$18.3
24-Stunden-Volumen:
11.38M
Relative Volume:
1.59
Marktkapitalisierung:
$9.35B
Einnahmen:
$10.89B
Nettoeinkommen (Verlust:
$-241.00M
KGV:
-68.56
EPS:
-0.2656
Netto-Cashflow:
$340.00M
1W Leistung:
-21.41%
1M Leistung:
-23.68%
6M Leistung:
-40.70%
1J Leistung:
-49.23%
1-Tages-Spanne:
$18.05
$18.40
1-Wochen-Bereich:
$18.05
$23.21
52-Wochen-Spanne:
$18.05
$37.74
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Vergleichen Sie BAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
18.21 | 9.49B | 10.89B | -241.00M | 340.00M | -0.2656 |
|
ISRG
Intuitive Surgical Inc
|
544.21 | 189.40B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
177.30 | 51.22B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
ALC
Alcon Inc
|
73.88 | 36.53B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
RMD
Resmed Inc
|
248.95 | 36.04B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
WST
West Pharmaceutical Services Inc
|
279.78 | 20.29B | 2.96B | 487.70M | 344.00M | 6.6758 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Herabstufung | Argus | Buy → Hold |
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Class Action Filed Against Baxter International, Inc. (BAX) - GlobeNewswire
Deadline Alert: Baxter International, Inc. (BAX) - GlobeNewswire
Deadline Alert: Baxter International, Inc. (BAX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
Lowey Dannenberg Notifies Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $250,000 in Losses to Contact the Firm - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International - PR Newswire
Baxter International, Inc. Securities Fraud Class Action Lawsuit - GuruFocus
Baxter International, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before December 15, 2025 to Discuss Your RightsBAX - Morningstar
United States Vitiligo Forecast Report 2025: A $320+ Million Market by 2033 Featuring Incyte, BMS, Clinuvel Pharmaceuticals, Astellas Pharma, Baxter, Pfizer, Dr. Reddy's LaboratoriesResearchAndMarkets.com - FinancialContent
Investor Alert: Deadline Approaching to Join Baxter International, Inc. (BAX) Class ActionContact Levi & Korsinsky - The Globe and Mail
What Developments Are Shaping the Narrative for Baxter International’s Future? - Yahoo! Finance Singapore
Baxter International (BAX) Stock Plunges on Q3 2025 Revenue Miss and Guidance CutNews and Statistics - IndexBox
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm - Lelezard
2025-11-03 | December 15, 2025 Deadline Approaching: Join Class Action Against Baxter International, Inc. (BAX)Contact Levi & Korsinsky | NYSE:BAX | Press Release - Stockhouse
Is Wall Street Bullish or Bearish on Baxter International Stock? - FinancialContent
BAXTER INTERNATIONAL INC. (NYSE: BAX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Baxter ... - Bluefield Daily Telegraph
BAXTER INTERNATIONAL INC. (NYSE: BAX) SHAREHOLDER ALERT - GlobeNewswire
Why Baxter International Inc. stock is a must watch ticker2025 Performance Recap & Advanced Technical Analysis Signals - newser.com
Key facts: Baxter International halts Novum LVP shipments; class action filed - TradingView
Research Alert: CFRA Keeps Sell Rating On Shares Of Baxter International Inc. - 富途牛牛
Baxter International (NYSE:BAX) Price Target Cut to $19.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Baxter International Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International - Newsfile
Cooke & Bieler LP Increases Holdings in Baxter International Inc. $BAX - MarketBeat
The Goldman Sachs Group Lowers Baxter International (NYSE:BAX) Price Target to $22.00 - Defense World
Baxter International (NYSE:BAX) Stock Rating Lowered by Argus - Defense World
Baxter International Stock Hits Day Low of $18.44 Amid Price Pressure - Markets Mojo
UBS Group Issues Pessimistic Forecast for Baxter International (NYSE:BAX) Stock Price - Defense World
2025-11-01 | December 15, 2025 Deadline Approaching: Join Class Action Against Baxter International, Inc. (BAX)Contact Levi & Korsinsky | NYSE:BAX | Press Release - Stockhouse
Baxter International Inc. stock trend outlook and recovery path2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Baxter International Inc. (NYSE:BAX) Q3 2025 Earnings Call Transcript - Insider Monkey
Jefferies Financial Group Has Lowered Expectations for Baxter International (NYSE:BAX) Stock Price - MarketBeat
Evercore ISI Issues Pessimistic Forecast for Baxter International (NYSE:BAX) Stock Price - MarketBeat
Baxter International (NYSE:BAX) Rating Lowered to "Hold" at Argus - MarketBeat
Forecasting Baxter International Inc. price range with options dataJuly 2025 Market Mood & Weekly Setup with High ROI Potential - newser.com
Is Baxter International Inc. stock a good choice for value investorsJuly 2025 Outlook & Consistent Profit Alerts - newser.com
Baxter Q3 2025 sales increase 5% to USD 2.84B - Medical Buyer
Baxter International (NYSE:BAX) Announces Quarterly Earnings Results - MarketBeat
Baxter International’s Earnings Call: Growth Amid Challenges - TipRanks
Citigroup Lowers Price Target for Baxter Intl (BAX) to $21 | BAX Stock News - GuruFocus
Why Baxter (BAX) Shares Are Sliding Today - TradingView
Baxter International (BAX): Losses Worsen as Investors Weigh Turnaround Hopes Against Ongoing Financial Risks - Sahm
Class Action Filed Against Baxter International, Inc. (BAX) Seeking Recovery for Investors – ... - Bluefield Daily Telegraph
Class Action Filed Against Baxter International, Inc. (BAX) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Baxter International (NYSE:BAX) Hits New 1-Year LowHere's What Happened - MarketBeat
BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Goldman Sachs Lowers Price Target for Baxter Intl (BAX) to $22.0 - GuruFocus
Argus Research Downgrades Baxter International Inc(BAX.US) to Hold Rating - 富途牛牛
UBS Maintains Neutral Rating on Baxter Intl (BAX), Lowers Price Target to $21 | BAX Stock News - GuruFocus
Baxter Intl (BAX) Downgraded by Argus Research to Hold | BAX Sto - GuruFocus
Stock Traders Buy High Volume of Put Options on Baxter International (NYSE:BAX) - MarketBeat
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):